Sunil Singhania trimmed his stake in Suven Life Sciences Limited from 1.13% to 1.00% through Abakkus Diversified Alpha Fund, selling 1,68,636 shares.
A clinical-stage biopharmaceutical company engaged in the acquisition, development, and commercialization of novel therapeutics for treating neurodegenerative disorders. Suven Life Sciences operates across research, analytics, and technology platforms to advance its pipeline of investigational drugs targeting diseases affecting the nervous system. The company focuses on bringing innovative treatment solutions to patients suffering from neurological conditions through rigorous clinical development processes.
The man who grew Reliance Mutual Fund's equity AUM from ₹200 Cr to nearly ₹80,000 Cr, one of the greatest fund management runs in Indian history. After leaving Reliance, Sunil Singhania launched Abakkus Asset Management (2018), which now manages ~₹36,700 Cr. Voted Best Fund Manager by Outlook Business (2016 & 2017). First Indian elected to the CFA Institute Board of Governors. His direct disclosed equity portfolio has consistently backed emerging industrials and financials before they became consensus.
